Hybio Pharmaceutical（Wuhan）Co.,Ltd.

Certificate of Analysis

DE202509-007 QC2-P12-01

Product Name	Tirzepatide	Batch Number	0422502A
Manufacture Date	May.14,2025	Delivery Quantity	30g
Test Date	May.19,2025	Report Date	Sep.12, 2025
Retest Date	May.13,2027	Storage	Store under -20±5℃ without direct sunlight after sealing
Test Standard	2-TSF-0052 Tirzepatide quality specification (Version 3.0)		

Test Item	Specification	Result
[Character]		
Appearance	White or off-white powder or loose lump	White powder
Hygroscopicity	Has hygroscopic properties,with a hygroscopic weight gain of less than 15% but not less than 2%	Conform(12%)
Solubility	Freely soluble in water,almost insoluble or insoluble in acetonitrile	Conform
Specific optical rotation	-25°~ -35°(calculated with reference to the anhydrous and sodium ion-free)	-30°
[Identification]		
UPLC	The RT of the main peak of sample in the assay test should be consistent with that of the reference.	Conform
MS	The monoisotopic molecular weight of the sample should be 4810.5±0.5Da	4810.6Da
Peptide mapping	The retention time of characteristic peaks P1 to P5 in the chromatogram of the sample solution is consistent with the retention time of the reference solution	Conform
[Check]		
pH	6.0~8.5	7.1
Water content	≤10.0%	3.5%
Clarity and color of solution	The solution is colorless and clear	conform
Sodium ion	≤3.0%	1.1%

Add: No.9, Lankong West Street, Hengdian Street, Huangpi District, Wuhan City, China
Tel: +86-27-59300199
Web: www.hybio.com.cn

Hybio Pharmaceutical（Wuhan）Co.,Ltd.

Certificate of Analysis

DE202509-007 QC2-P12-01

Product Name	Tirzepatide	Batch Number	0422502A
Test Standard	2-TSF-0052 Tirzepatide quality specification (Version 3.0)		

Test Item	Specification	Result
Amino acid analysis	Asp: 1.8～2.2	2.0
	Ser: 4.0～5.0	4.3
	Glu: 3.6～4.4	4.0
	Gly: 3.6～4.4	4.0
	Thr: 1.5～2.2	1.9
	Ala: 3.6～4.4	4.0
	Pro: 3.6～4.4	4.1
	Tyr: 1.8～2.2	2.0
	Aib: 1.8～2.2	1.9
	Lys: 1.8～2.2	2.0
	Val: 0.9～1.1	1.0
	Ile: 2.7～3.3	3.0
	Leu: 1.8～2.2	2.0
	Phe: 1.8～2.2	2.0
Related substance	Method I	
	Impurity A≤0.15%	0.10%
	Method II	
	Impurity B≤0.12%	0.05%
	Impurities at position C and D(Deduction Method III impurity C and Impurity D)＜0.10%	0.02%
	Impurities at position E(Deduction Method III impurity E)＜0.10%	0.02%
	Impurity G＜0.15%	N.D.
	Impurities at position H(Deduction Method III impurity H)＜0.10%	N.D.
	Impurity I≤0.20%	<0.05%
	Impurity J≤0.20%	N.D.
	Other single impurity＜0.10%	0.06%
	Total impurities(Impurity A in method I) ≤2.0%	0.53%
	Method III	
	Impurity C＜0.10%	0.01%
	Impurity D＜0.10%	0.02%
	Impurity E＜0.10%	0.04%
	Impurity H＜0.13%	0.05%

Add: No.9, Linkong West Street, Hengdian Street, Huangpi District, Wuhan City, China
Tel：+86-27-59300199 Web: www.hybio.com.cn

Hybio Pharmaceutical（Wuhan）Co.,Ltd.

Certificate of Analysis

DE202509-007 QC2-P12-01

Product Name	Tirzepatide	Batch Number	0422502A
Test Standard	2-TSF-0052 Tirzepatide quality specification (Version 3.0)		

Test Item	Specification	Result
Polymer impurities	≤0.20%	0.04%
Residual solvent	Methanol: ≤3000ppm	N.D.
	Acetonitrile: ≤410ppm	N.D.
Bacterial endotoxins	<5EU/mg	<2.5EU/mg
Microbial limits	TAMC: ≤2×10²cfu/g	TAMC: <1×10cfu/g
	TYMC: ≤5×10¹cfu/g	TYMC: <1×10cfu/g
[Assay]		
Assay	95.0%~105.0% (calculated with reference to the anhydrous and sodium)	98.9%
	No content below	

DISTRIBUIDO POR METAPHARMACEUTICAL INDUSTRIAL SLU

23 SEP 2025

META PHARMACEUTICAL

Conclusion	Tests were performed according to2-TSF-0052 Tirzepatide quality specification (Version 3.0), the results conform with specification.		
Remark	R&D only.		
Reporter	Heng xu	Date	Sep. 12, 2025
Reviewer	Qi Fang	Date	Sep. 12. 2025

Add: No.9, Linkong West Street, Hengdian Street, Huangpi District, Wuhan City, China
Tel：+86-27-59300199 Web: www.hybio.com.cn